Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma

Marta Mazzocco, Matteo Martini, Antonio Rosato, Elisabetta Stefani, Andrea Matucci, Silvia Dalla Santa, Francesco De Sanctis, Stefano Ugel, Sara Sandri, Giovanna Ferrarini, Tiziana Cestari, Sergio Ferrari, Paola Zanovello, Vincenzo Bronte, Silvia Sartoris

Research output: Contribution to journalArticlepeer-review


In the Sp6 mouse plasmacytoma model, a whole-cell vaccination with Sp6 cells expressing de novo B7-1 (Sp6/B7) induced anatomically localized and cytotoxic T cell (CTL) -mediated protection against wild-type (WT) Sp6. Both WT Sp6 and Sp6/B7 showed down-regulated expression of MHC H-2 Ld. Increase of H-2 Ld expression by cDNA transfection (Sp6/B7/Ld) raised tumour immune protection and shifted most CTL responses towards H-2 Ld-restricted antigenic epitopes. The tumour-protective responses were not specific for the H-2 Ld-restricted immunodominant AH1 epitope of the gp70 common mouse tumour antigen, although WT Sp6 and transfectants were able to present it to specific T cells in vitro. Gp70 transcripts, absent in secondary lymphoid organs of naive mice, were detected in immunized mice as well as in splenocytes from naive mice incubated in vitro with supernatants of CTL-lysed Sp6 cell cultures, containing damage-associated molecular patterns (DAMPs). It has been shown that Toll-like receptor triggering induces gp70 expression. Damage-associated molecular patterns are released by CTL-mediated killing of Sp6/B7-Sp6/B7/Ld cells migrated to draining lymph nodes during immunization and may activate gp70 expression and presentation in most resident antigen-presenting cells. The same could also apply for Mus musculus endogenous ecotropic murine leukaemia virus 1 particles present in Sp6-cytosol, discharged by dying cells and superinfecting antigen-presenting cells. The outcome of such a massive gp70 cross-presentation would probably be tolerogenic for the high-affinity AH1-gp70-specific CTL clones. In this scenario, autologous whole-tumour-cell vaccines rescue tumour-specific immunoprotection by amplification of subdominant tumour antigen responses when those against the immune dominant antigens are lost.

Original languageEnglish
Pages (from-to)33-49
Number of pages17
Issue number1
Publication statusPublished - Sep 1 2015


  • Cancer immunoediting
  • Cellular vaccines
  • Myeloma

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma'. Together they form a unique fingerprint.

Cite this